STAT3 and hepatocellular carcinoma: In the HCC microenvironment, IL-6 is released by the activated NF-κB pathway, and eventually, the NF-κB/IL-6/STAT3 pathway exerts a pro-tumor effect in inflammation-associated tumors, such as HCC [225, 226].